These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications. Aithal GP; Day CP; Kesteven PJ; Daly AK Lancet; 1999 Feb; 353(9154):717-9. PubMed ID: 10073515 [TBL] [Abstract][Full Text] [Related]
3. Genetic susceptibility to hemorrhagic complications during warfarin therapy. Tabrizi AR; Freeman BD; Buchman TG; Zehnbauer BA Surgery; 2001 May; 129(5):645-6. PubMed ID: 11331459 [No Abstract] [Full Text] [Related]
4. Genetic control of anticoagulation. Mannucci PM Lancet; 1999 Feb; 353(9154):688-9. PubMed ID: 10073506 [No Abstract] [Full Text] [Related]
11. Major bleeding caused by warfarin in a genetically susceptible patient. Bloch A; Ben-Chetrit E; Muszkat M; Caraco Y Pharmacotherapy; 2002 Jan; 22(1):97-101. PubMed ID: 11794436 [TBL] [Abstract][Full Text] [Related]
12. Mutations of the CYP2C9 gene and the response to warfarin. Yasar U; Oscarson M; Eliasson E; Sjöqvist F Surgery; 2001 Mar; 129(3):384. PubMed ID: 11231472 [No Abstract] [Full Text] [Related]
13. Reply to rebuttal: Gene variants of the cytochrome P450 CYP2C9 affect oral anticoagulation with warfarin. Margaglione M; Brancaccio V; Ciampa A; Di Minno G Thromb Haemost; 2001 Sep; 86(3):938. PubMed ID: 11583336 [No Abstract] [Full Text] [Related]
14. Influence of cytochrome P-450 CYP2C9 polymorphisms on warfarin sensitivity and risk of over-anticoagulation in patients on long-term treatment. Taube J; Halsall D; Baglin T Blood; 2000 Sep; 96(5):1816-9. PubMed ID: 10961881 [TBL] [Abstract][Full Text] [Related]
16. Association of CYP2C9 genotypes leading to high enzyme activity and colorectal cancer risk. Yasar U; Eliasson E; Dahl ML Carcinogenesis; 2002 Apr; 23(4):665; author reply 667-8. PubMed ID: 11960920 [No Abstract] [Full Text] [Related]
17. Interindividual variability in sensitivity to warfarin--Nature or nurture? Loebstein R; Yonath H; Peleg D; Almog S; Rotenberg M; Lubetsky A; Roitelman J; Harats D; Halkin H; Ezra D Clin Pharmacol Ther; 2001 Aug; 70(2):159-64. PubMed ID: 11503010 [TBL] [Abstract][Full Text] [Related]
18. Pharmacogenetics of warfarin elimination and its clinical implications. Takahashi H; Echizen H Clin Pharmacokinet; 2001; 40(8):587-603. PubMed ID: 11523725 [TBL] [Abstract][Full Text] [Related]
19. Validation of methods for CYP2C9 genotyping: frequencies of mutant alleles in a Swedish population. Yasar U; Eliasson E; Dahl ML; Johansson I; Ingelman-Sundberg M; Sjöqvist F Biochem Biophys Res Commun; 1999 Jan; 254(3):628-31. PubMed ID: 9920790 [TBL] [Abstract][Full Text] [Related]
20. Implications of cytochrome P450 2C9 polymorphism on warfarin metabolism and dosing. Redman AR Pharmacotherapy; 2001 Feb; 21(2):235-42. PubMed ID: 11213860 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]